CCC
TMO icon

Crescent Capital Consulting’s Thermo Fisher Scientific TMO Stock Holding History

Crescent Capital Consulting’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-750
Closed -$378K – 603
2021
Q2 		$378K Sell
750
-31
-4% -$14.6K 0.07% 125
2021
Q1 		$357K Buy
781
+21
+3% +$10K 0.08% 127
2020
Q4 		$354K Buy
+760
New +$356K 0.09% 115

Other funds holding TMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Crescent Capital Consulting's TMO Position: Q3 2021 in Review

Crescent Capital Consulting sold out of Thermo Fisher Scientific (TMO) in Q3 2021, closing a stake of 750 shares — an estimated $378K sold.

Crescent Capital Consulting first reported a position in TMO in Q4 2020 and held it in 3 quarters. The position peaked at $378K in Q2 2021. 2,128 funds tracked by Wall St. Rank hold TMO as of Q3 2021.

  • Crescent Capital Consulting reported no remaining Thermo Fisher Scientific position as of Q3 2021 after selling out during the quarter.
  • Crescent Capital Consulting sold 750 Thermo Fisher Scientific shares in Q3 2021, an estimated $378K.
  • Crescent Capital Consulting first reported a position in Thermo Fisher Scientific in Q4 2020 and held it in 3 quarters.
  • Crescent Capital Consulting's Thermo Fisher Scientific position peaked at $378K in Q2 2021.
  • 2,128 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q3 2021.

Based on Crescent Capital Consulting's 13F filing for Q3 2021, filed 12 Oct 2021.